Abstract
Objective The visual system is a significant site of pathology in psychosis spectrum disorders. However, there is limited research investigating human visual cortex (VC) subregions in this population. Using data from the Bipolar-Schizophrenia Network on Intermediate Phenotypes Consortium (BSNIP-1, BSNIP-2, PARDIP), this study examined structural measures in VC subregions in individuals with psychosis spectrum disorders.
Methods Cortical surface area and thickness in five VC subregions (hOc1, hOc2, hOc3v, hOc4v, MT) were quantified using FreeSurfer v7.1.0 and compared between individuals with psychosis (n=1211) and healthy controls (n=734). Regional specificity was examined by controlling for total surface area or mean cortical thickness. ComBat was used to harmonize scanner effects. Associations between VC measures and symptom severity, cognition, and childhood trauma scores were assessed.
Results Individuals with psychosis demonstrated smaller surface area in hOc1, hOc2, and hOc3v, and lower cortical thickness in all five VC subregions compared to healthy controls. Thickness reductions in hOc1, hOc4v, and MT were regionally specific. hOc4v and MT were among the top three regions exhibiting the most robust cortical thickness deficits (d = −0.38 to −0.40) across all VC and Desikan-Killiany brain regions. Lower thickness in mid-level visual subregions were associated with greater positive symptoms, poorer cognition, and higher childhood trauma scores.
Conclusions This study demonstrates that the visual cortex is among the most profoundly affected brain regions in psychotic disorders. Different patterns of area and thickness changes across early and mid-level visual subregions, along with their varying associations with clinical measures, suggest distinct developmental and disease-related influences.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by National Institute of Health, National Institute of Mental Health (NIMH): MH096942, MH078113, MH096900, MH103366, MH096913, MH077851, MH096957, MH077945, MH077852, MH077862, MH103368. HBT was supported by Harvard Medical School's Dupont Warren and Livingston Fellowships, McLean Hospital's Pope-Hintz Fellowship, and the Brain and Behavior Research Foundation's NARSAD Young Investigator Grant. SK was supported by the University of Chicago Magnetic Resonance Imaging Research Center (S10OD018448). PL was supported by the NIMH (K23MH122701).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
B-SNIP and PARDIP protocols were approved by local Institutional Review Boards across study sites (Baltimore, MD; Boston, MA; Chicago, IL; Dallas, TX; Athens, GA; Hartford, CT; Detroit, MI).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵* denotes shared senior authorship.
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.